Dr. Bicky Thapa, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 39
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 1017948 -
Hematology & Oncology Physician
WI license 71212 -
Hospitalist Physician
WI license 71212
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
Medical groups
- Dana-Farber Cancer Institute, Inc. (684 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 39
- Services billed
- 52
- Patients’ average age
- 72
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $228 in total to this clinician.
| Tempus Ai, Inc | $110 |
|---|---|
| Exelixis Inc. | $104 |
| Astellas Pharma US Inc | $14.00 |
| Food and Beverage | $228 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,170 in research payments for these studies, mostly to the institutions running them.
- Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Deciphera Pharmaceuticals Inc. · Recruiting · NCT06966024
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.